KSCHIRT: Investigating the Efficacy of BNC-1 in Alleviating Tau Pathology in TBI

Grants and Contracts Details


Currently, therapeutic options for treatment of the secondary wave of neurodegeneration associated with traumatic brain injury (TBI) remain limited. Previous studies demonstrate a significant role for tau hyperphosphorylation in neurodegeneration following TBI although the mechanism by leading to increased tau pathology remains unclear. Based on recent studies that demonstrate a role for TAK1 kinase in tau hyperphosphorylation we propose to test the hypothesis that TAK1 inhibition mediated by a novel small molecule TAK1 kinase inhibitor developed in our lab will significantly decrease tau hyperphosphorylation and behavioral deficits in a mouse model of TBI.
Effective start/end date2/1/241/31/27


  • KY Spinal Cord and Head Injury Research Trust: $100,000.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.